CDKN2A and myasthenia gravis: For all these reasons, we designed the present study to deeply investigate MGMT, MLH1, CDKN2A, and RASSF1A methylation levels in a cohort of Caucasian TAMG samples large enough to evaluate the contribution of tumor stage and histology, as well as those of the MG clinical subtypes, to the observed findings.